In this issue of Brain Communications, Desai and colleagues3 undertook an extensive analytical approach to investigate if phosphodiesterase type 5 (PDE-5) inhibitors (sildenafil and tadalafil) could be potential therapies for Alzheimer’s disease and related dementias (ADRD). Here, PDE5A is linked to Alzheimer disease.